MA51795A - Oligonucléotides pour moduler l'expression de tmem106b - Google Patents
Oligonucléotides pour moduler l'expression de tmem106bInfo
- Publication number
- MA51795A MA51795A MA051795A MA51795A MA51795A MA 51795 A MA51795 A MA 51795A MA 051795 A MA051795 A MA 051795A MA 51795 A MA51795 A MA 51795A MA 51795 A MA51795 A MA 51795A
- Authority
- MA
- Morocco
- Prior art keywords
- tmem106b
- oligonucleotides
- modulate
- expression
- Prior art date
Links
- 101000834926 Homo sapiens Transmembrane protein 106B Proteins 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 102100026232 Transmembrane protein 106B Human genes 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18156142 | 2018-02-09 | ||
| US201862669251P | 2018-05-09 | 2018-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51795A true MA51795A (fr) | 2020-12-16 |
Family
ID=65433647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051795A MA51795A (fr) | 2018-02-09 | 2019-02-08 | Oligonucléotides pour moduler l'expression de tmem106b |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11485975B2 (fr) |
| EP (1) | EP3749766A1 (fr) |
| JP (1) | JP7281474B2 (fr) |
| KR (1) | KR20200108315A (fr) |
| CN (1) | CN111868245B (fr) |
| AU (1) | AU2019219194A1 (fr) |
| BR (1) | BR112020016170A2 (fr) |
| CA (1) | CA3088071A1 (fr) |
| CL (1) | CL2020002038A1 (fr) |
| CR (1) | CR20200346A (fr) |
| IL (1) | IL276357A (fr) |
| MA (1) | MA51795A (fr) |
| MX (1) | MX2020008290A (fr) |
| PE (1) | PE20211197A1 (fr) |
| RU (1) | RU2020125769A (fr) |
| SG (1) | SG11202007093YA (fr) |
| WO (1) | WO2019154979A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021097437A1 (fr) * | 2019-11-14 | 2021-05-20 | The Board Of Regents Of The University Of Oklahoma | Traitements du cancer de la prostate par interférence d'oligonucléotides |
| WO2021231211A1 (fr) * | 2020-05-11 | 2021-11-18 | Genentech, Inc. | Inhibiteurs de la composante c1s du complément pour le traitement d'une maladie neurologique, et compositions associées, systèmes et procédés d'utilisation de ceux-ci |
| TW202340468A (zh) | 2022-01-10 | 2023-10-16 | 中國大陸商杭州浩博醫藥有限公司 | B型肝炎病毒(hbv)表現之調節 |
| CN118613268A (zh) * | 2022-01-20 | 2024-09-06 | 基因泰克公司 | 用于调节tmem106b表达的反义寡核苷酸 |
| KR20250134232A (ko) * | 2023-01-10 | 2025-09-10 | 오스퍼바이오 테라퓨틱스 인크. | 사용하기 위한 변형된 다중-세그먼트화 안티센스 올리고뉴클레오티드 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| DE69829760T3 (de) | 1997-09-12 | 2016-04-14 | Exiqon A/S | Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga |
| KR100573231B1 (ko) | 1999-02-12 | 2006-04-24 | 상꾜 가부시키가이샤 | 신규 뉴클레오시드 및 올리고뉴클레오티드 유사체 |
| AU776362B2 (en) | 1999-05-04 | 2004-09-09 | Roche Innovation Center Copenhagen A/S | L-ribo-LNA analogues |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| KR100909681B1 (ko) | 2000-12-01 | 2009-07-29 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자 |
| AU2002303176A1 (en) | 2001-03-27 | 2002-10-15 | University Of Delaware | Genomics applications for modified oligonucleotides |
| IL159756A0 (en) | 2001-07-12 | 2004-06-20 | Univ Massachusetts | IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| US8090542B2 (en) | 2002-11-14 | 2012-01-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
| EP2752488B1 (fr) | 2002-11-18 | 2020-02-12 | Roche Innovation Center Copenhagen A/S | Conception antisens |
| EP2141234B1 (fr) | 2003-03-21 | 2016-04-27 | Roche Innovation Center Copenhagen A/S | Analogues de petits Arn interférents (SIRNA) |
| AU2005248147A1 (en) | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| EP2397563A3 (fr) | 2004-09-17 | 2012-07-18 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| WO2007031091A2 (fr) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Composes antagonistes d'arn de modulation de l'expression de p21 ras |
| CA2640171C (fr) | 2006-01-27 | 2014-10-28 | Isis Pharmaceuticals, Inc. | Analogues d'acides nucleiques bicycliques modifies en position 6 |
| EP2002004B1 (fr) | 2006-03-23 | 2015-10-14 | Roche Innovation Center Copenhagen A/S | Arn interférant court segmenté à l'intérieur |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| JP5441688B2 (ja) | 2006-05-11 | 2014-03-12 | アイシス ファーマシューティカルズ， インコーポレーテッド | ５’修飾二環式核酸類似体 |
| DK2092065T4 (da) | 2006-10-18 | 2019-10-21 | Ionis Pharmaceuticals Inc | Antisense-forbindelser |
| EP2170917B1 (fr) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | Analogues d'acides nucléiques bicycliques pontés par aminométhylène n-substitué |
| ES2386492T3 (es) | 2007-06-08 | 2012-08-21 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos carbocíclicos |
| CN101796062B (zh) | 2007-07-05 | 2014-07-30 | Isis制药公司 | 6-双取代双环核酸类似物 |
| WO2009067647A1 (fr) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Analogues d'acide nucléique alpha-l-bicyclique carbocyclique |
| DK2356129T3 (da) | 2008-09-24 | 2013-05-13 | Isis Pharmaceuticals Inc | Substituerede alpha-L-bicykliske nukleosider |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| CN102325534B (zh) | 2008-12-18 | 2016-02-17 | 戴瑟纳制药公司 | 延长的dicer酶底物和特异性抑制基因表达的方法 |
| SG10202109219SA (en) | 2009-05-02 | 2021-10-28 | Genzyme Corp | Gene therapy for neurodegenerative disorders |
| WO2011017521A2 (fr) | 2009-08-06 | 2011-02-10 | Isis Pharmaceuticals, Inc. | Analogues d'acides nucléiques cyclohexoses bicycliques |
| EP2580228B1 (fr) | 2010-06-08 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | 2' amino- et 2' thio-nucléosides bicycliques substitués et composés oligomères préparés à partir de ces derniers |
| WO2011154542A1 (fr) | 2010-06-11 | 2011-12-15 | Artisense Pharma Gmbh | Procédé pour une modification sélective d'oligonucléotides |
| AU2011325956B2 (en) * | 2010-11-12 | 2016-07-14 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| EP3467109A1 (fr) | 2011-02-08 | 2019-04-10 | Ionis Pharmaceuticals, Inc. | Composés oligomères comprenant des nucléotides bicycliques et leurs utilisations |
| KR20140031217A (ko) | 2011-04-20 | 2014-03-12 | 로슈 글리카트 아게 | 혈액-뇌 차단벽의 pH 의존적 통과를 위한 방법 및 구축물 |
| EP2742056B2 (fr) | 2011-08-11 | 2020-06-10 | Ionis Pharmaceuticals, Inc. | Composés antisens sélectifs et utilisations de ceux-ci |
| EP2850092B1 (fr) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Analogues tricycliques d'acide nucléique |
| BR112014028634A2 (pt) | 2012-05-16 | 2017-06-27 | Rana Therapeutics Inc | composições e métodos para modulação da expressão de utrn |
| CA2873801A1 (fr) * | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions et methodes pour moduler l'expression de apoa1 et de abca1 |
| US20150141320A1 (en) * | 2012-05-16 | 2015-05-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
| JP6452614B2 (ja) | 2012-11-15 | 2019-01-16 | ロシュ イノベーション センター コペンハーゲン エーエス | オリゴヌクレオチドコンジュゲート |
| KR102287532B1 (ko) | 2014-01-30 | 2021-08-11 | 에프. 호프만-라 로슈 아게 | 생분해성 컨쥬게이트를 갖는 폴리 올리고머 화합물 |
| US20150231151A1 (en) | 2014-02-19 | 2015-08-20 | University Of Houston System | Compositions and methods for the treatment of neurodegenerative diseases |
| CN104450621B (zh) * | 2014-09-30 | 2018-10-19 | 首都医科大学附属北京口腔医院 | Wdr63基因在间充质干细胞骨向和牙向分化过程中的调控方法 |
| EP3253871A1 (fr) * | 2015-02-04 | 2017-12-13 | Bristol-Myers Squibb Company | Oligonucléotides lna à flancs alternés |
| UY36550A (es) * | 2015-02-04 | 2016-08-31 | Roche Innovation Ct Copenhagen As | Oligómeros antisentido de tau y sus usos |
-
2019
- 2019-02-08 KR KR1020207022883A patent/KR20200108315A/ko not_active Ceased
- 2019-02-08 CR CR20200346A patent/CR20200346A/es unknown
- 2019-02-08 CA CA3088071A patent/CA3088071A1/fr not_active Abandoned
- 2019-02-08 BR BR112020016170-5A patent/BR112020016170A2/pt not_active Application Discontinuation
- 2019-02-08 MA MA051795A patent/MA51795A/fr unknown
- 2019-02-08 SG SG11202007093YA patent/SG11202007093YA/en unknown
- 2019-02-08 RU RU2020125769A patent/RU2020125769A/ru not_active Application Discontinuation
- 2019-02-08 WO PCT/EP2019/053116 patent/WO2019154979A1/fr not_active Ceased
- 2019-02-08 EP EP19705306.9A patent/EP3749766A1/fr active Pending
- 2019-02-08 CN CN201980020478.1A patent/CN111868245B/zh active Active
- 2019-02-08 AU AU2019219194A patent/AU2019219194A1/en not_active Abandoned
- 2019-02-08 PE PE2020001186A patent/PE20211197A1/es unknown
- 2019-02-08 MX MX2020008290A patent/MX2020008290A/es unknown
- 2019-02-08 JP JP2020542377A patent/JP7281474B2/ja active Active
-
2020
- 2020-07-28 IL IL276357A patent/IL276357A/en unknown
- 2020-08-05 CL CL2020002038A patent/CL2020002038A1/es unknown
- 2020-08-06 US US16/987,030 patent/US11485975B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111868245B (zh) | 2024-11-19 |
| US20210054383A1 (en) | 2021-02-25 |
| JP2021514182A (ja) | 2021-06-10 |
| US11485975B2 (en) | 2022-11-01 |
| RU2020125769A (ru) | 2022-03-10 |
| BR112020016170A2 (pt) | 2020-12-15 |
| AU2019219194A1 (en) | 2020-08-06 |
| CA3088071A1 (fr) | 2019-08-15 |
| IL276357A (en) | 2020-09-30 |
| JP7281474B2 (ja) | 2023-05-25 |
| PE20211197A1 (es) | 2021-07-01 |
| EP3749766A1 (fr) | 2020-12-16 |
| CN111868245A (zh) | 2020-10-30 |
| MX2020008290A (es) | 2020-09-25 |
| RU2020125769A3 (fr) | 2022-03-10 |
| CR20200346A (es) | 2020-10-19 |
| WO2019154979A1 (fr) | 2019-08-15 |
| CL2020002038A1 (es) | 2020-10-23 |
| SG11202007093YA (en) | 2020-08-28 |
| KR20200108315A (ko) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3768854A4 (fr) | Modulation de l'expression de hsd17b13 | |
| EP3724780A4 (fr) | Évolution d'architectures pour réseaux neuronaux multitâches | |
| EP3607023C0 (fr) | Solutions micellaires pour traitement de formations d'hydrocarbures | |
| EP3526328A4 (fr) | Polythérapie pour l'inhibition de c3 | |
| EP3853365A4 (fr) | Modulateurs de l'expression de pnpla3 | |
| EP3442488A4 (fr) | Compositions pour l'application topique de composés | |
| MA51795A (fr) | Oligonucléotides pour moduler l'expression de tmem106b | |
| EP3906029A4 (fr) | Inhibiteurs de l'interaction ménine-mll | |
| EP3431075A4 (fr) | Forme galénique d'édaravone | |
| EP3692028A4 (fr) | Inhibition de la peptidase 30 spécifique de l'ubiquitine | |
| MA53924A (fr) | Modulateurs de l'expression d'apol1 | |
| EP3700516A4 (fr) | Inhibiteurs de l'induction de dux4 pour la régulation de la fonction musculaire | |
| EP3645039A4 (fr) | Utilisation d'anticorps anti-fam19a5 pour le traitement de la fibrose | |
| EP3645040A4 (fr) | Utilisation d'anticorps anti-fam19a5 pour le traitement de cancers | |
| EP3630102A4 (fr) | Formulations pour le traitement d'un trouble de stress post-traumatique | |
| EP3601569A4 (fr) | Modulateurs de l'expression de pcsk9 | |
| EP3476478A4 (fr) | Composition pour l'élimination de composés soufrés | |
| EP3634426A4 (fr) | Compositions pour le traitement d'une fibrose | |
| EP3397288A4 (fr) | Méthodes pour diminuer l'expression de l'ataxine-2 | |
| EP3541379A4 (fr) | Compositions pour le traitement de l'hypertension | |
| EP3723768A4 (fr) | Composés pour le traitement et la prévention de pathologies médiées par l'histone extracellulaire | |
| EP3773221A4 (fr) | Traitement pour l'hydrocéphalie | |
| MA51645A (fr) | Modulateurs de l'expression de dnm2 | |
| EP3716966A4 (fr) | Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie | |
| EP3403655A4 (fr) | Composition pour augmenter l'expression de pgc-1 |